BriaCell Prices Public Offering at $5.59 per Unit, Nearly 49% Discount
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Should l Buy BCTX?
Source: stocktwits
- Public Offering Pricing: BriaCell announced a public offering of 5.37 million units priced at $5.59 each, which includes one common share and one warrant, representing a nearly 49% discount from Tuesday's closing price of $10.92, indicating market concerns about the company's future.
- Use of Proceeds: The offering is expected to close on January 15, with BriaCell planning to use the net proceeds for working capital and general corporate purposes, despite having $10.2 million in cash and cash equivalents as of October 31, highlighting potential financial pressures.
- Stock Price Volatility: Following the announcement of the public offering, BriaCell's shares fell over 10% in after-hours trading, even though they surged nearly 43% on Tuesday due to positive news of a patient achieving complete resolution of lung metastasis, reflecting significant investor sentiment swings.
- Investor Sentiment Shift: Despite the negative impact of the offering announcement on stock price, retail sentiment on Stocktwits for BriaCell surged from neutral to 'extremely bullish' (94/100), suggesting that investors still hold confidence in the company's future potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCTX
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BriaCell Treatment Shows Significant Efficacy in Cancer Patients
- Significant Clinical Efficacy: The Bria-IMT treatment achieved complete resolution of right temporal lobe metastasis in a 66-year-old female patient, who survived 27 months post-enrollment, demonstrating the therapy's potential in heavily pre-treated patients.
- Evidence of Immune Activation: CD8 ImmunoPET imaging revealed a significant increase in CD8+ T cells in the cervical lymph nodes post-Bria-IMT treatment, indicating immune system activation that may contribute to long-term survival.
- Study Scale and Results: Among 54 heavily pre-treated metastatic breast cancer patients, 37 received the Bria-IMT regimen, with no reported treatment discontinuations related to Bria-IMT to date, indicating good safety and tolerability of the therapy.
- Future Research Prospects: The ongoing Phase 3 clinical trial (NCT06072612) by BriaCell will further validate the efficacy of Bria-IMT, potentially bringing new hope to cancer treatment.
See More
BriaCell's New Therapy Significantly Extends Survival in Breast Cancer Patients
- Impressive Survival Data: As of the latest assessment, nine patients treated with Bria-IMT since 2022 have survived over 18 months, significantly exceeding benchmarks for standard therapies, indicating the potential efficacy of this treatment.
- Strong Treatment Continuity: No Bria-IMT-related discontinuations have been reported to date, suggesting good tolerability of the regimen among patients, which may provide new treatment options for heavily pre-treated individuals.
- Clinical Trial Progress: The Bria-IMT regimen continues under Fast Track Designation from the US FDA, expected to offer more effective treatment options for late-stage breast cancer patients, addressing the urgent market need for new therapies.
- Future Research Directions: BriaCell's ongoing pivotal Phase 3 study will focus on overall survival as its primary endpoint, aiming to further validate the efficacy of Bria-IMT and promote its broader acceptance in clinical applications.
See More
U.S. Retail Sales Rise 0.6% MoM, Tech Stocks Decline
- Retail Sales Surge: U.S. retail sales increased by 0.6% month-over-month in November, marking the largest surge since July, indicating a potential rebound in consumer spending that could positively impact economic recovery.
- Tech Stock Decline: Information technology stocks fell by 1.3% on Wednesday, reflecting market concerns over the tech sector, which may affect investor confidence and lead to capital outflows.
- High-Risk Stock Surge: High Roller Technologies, Inc. (NYSE:ROLR) shares skyrocketed 289% to $13.64 after announcing a binding Letter of Intent with Crypto.com to launch an event-based prediction markets product in the U.S., demonstrating strong market demand for innovative offerings.
- IPO Impact: Briacell Therapeutics Corp. (NASDAQ:BCTX) priced its $30 million public offering at $5.59 per unit, leading to a 53% drop in its stock price to $5.09, reflecting market sensitivity to financing activities.
See More
Bank of America Reports Q4 Net Income of $7.6 Billion, Exceeding Expectations
- Earnings Highlight: Bank of America (BAC) reported a net income of $7.6 billion for Q4 FY2025, down from $6.8 billion a year ago, yet its EPS of 98 cents surpassed the analyst consensus estimate of 96 cents, indicating stable profitability amidst market fluctuations.
- Revenue Growth: The bank's revenue net of interest expense increased by 7% year-over-year to $28.532 billion, exceeding the analyst consensus estimate of $27.944 billion, reflecting strong performance and effective cost management in a competitive landscape.
- Market Dynamics: While U.S. stocks traded lower overall, with the Nasdaq Composite falling over 100 points, energy stocks rose by 0.9%, indicating a divergence in market performance that may present investors with opportunities to reassess their portfolios.
- Economic Indicators: U.S. retail sales increased by 0.6% month-over-month in November, marking the largest surge since July, suggesting a rebound in consumer spending that could positively impact future economic growth.
See More
Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%
- Glaukos Sales Projection: Glaukos Corp anticipates FY25 sales of $507 million, yet its shares fell 12.1% in pre-market trading, indicating market concerns about its growth outlook despite the positive sales forecast.
- Briacell's Sharp Decline: Briacell Therapeutics' announcement of a $30 million public offering led to a staggering 53.1% drop in its stock price during pre-market trading, reflecting investor apprehension regarding the financing strategy.
- Trip.com Investigation Impact: Trip.com Group confirmed it is under investigation by China's SAMR for potential anti-monopoly violations, resulting in a 9.3% decline in its pre-market stock price, which may adversely affect its market performance and investor confidence.
- Pearson Trading Update: Pearson PLC's trading update for 2025 caused its shares to drop 7.2% in pre-market trading, indicating a cautious market sentiment regarding its future performance.
See More
BriaCell Therapeutics Prices Public Offering at $5.59 per Unit for $30 Million
- Public Offering Details: BriaCell Therapeutics announced a public offering of 5.367 million units priced at $5.59 each, aiming for gross proceeds of approximately $30 million, which will fund working capital and general corporate purposes.
- Warrant Information: Each unit consists of one common share and one warrant, the latter allowing purchase of common shares at an exercise price of $6.93, expiring five years post-issuance, enhancing potential returns for investors.
- Stock Price Impact: Following the announcement, BCTX's stock plummeted 54.12% to $5.01, reflecting a highly negative market reaction despite a previous surge to $12.10 due to positive results in treating breast cancer patients.
- Future Trading Arrangements: The warrants have been approved for listing on the Nasdaq Capital Market, expected to begin trading under the symbol
See More
BriaCell Treatment Shows Significant Efficacy in Cancer Patients
- Significant Clinical Efficacy: The Bria-IMT treatment achieved complete resolution of right temporal lobe metastasis in a 66-year-old female patient, who survived 27 months post-enrollment, demonstrating the therapy's potential in heavily pre-treated patients.
- Evidence of Immune Activation: CD8 ImmunoPET imaging revealed a significant increase in CD8+ T cells in the cervical lymph nodes post-Bria-IMT treatment, indicating immune system activation that may contribute to long-term survival.
- Study Scale and Results: Among 54 heavily pre-treated metastatic breast cancer patients, 37 received the Bria-IMT regimen, with no reported treatment discontinuations related to Bria-IMT to date, indicating good safety and tolerability of the therapy.
- Future Research Prospects: The ongoing Phase 3 clinical trial (NCT06072612) by BriaCell will further validate the efficacy of Bria-IMT, potentially bringing new hope to cancer treatment.
See More
BriaCell's New Therapy Significantly Extends Survival in Breast Cancer Patients
- Impressive Survival Data: As of the latest assessment, nine patients treated with Bria-IMT since 2022 have survived over 18 months, significantly exceeding benchmarks for standard therapies, indicating the potential efficacy of this treatment.
- Strong Treatment Continuity: No Bria-IMT-related discontinuations have been reported to date, suggesting good tolerability of the regimen among patients, which may provide new treatment options for heavily pre-treated individuals.
- Clinical Trial Progress: The Bria-IMT regimen continues under Fast Track Designation from the US FDA, expected to offer more effective treatment options for late-stage breast cancer patients, addressing the urgent market need for new therapies.
- Future Research Directions: BriaCell's ongoing pivotal Phase 3 study will focus on overall survival as its primary endpoint, aiming to further validate the efficacy of Bria-IMT and promote its broader acceptance in clinical applications.
See More
U.S. Retail Sales Rise 0.6% MoM, Tech Stocks Decline
- Retail Sales Surge: U.S. retail sales increased by 0.6% month-over-month in November, marking the largest surge since July, indicating a potential rebound in consumer spending that could positively impact economic recovery.
- Tech Stock Decline: Information technology stocks fell by 1.3% on Wednesday, reflecting market concerns over the tech sector, which may affect investor confidence and lead to capital outflows.
- High-Risk Stock Surge: High Roller Technologies, Inc. (NYSE:ROLR) shares skyrocketed 289% to $13.64 after announcing a binding Letter of Intent with Crypto.com to launch an event-based prediction markets product in the U.S., demonstrating strong market demand for innovative offerings.
- IPO Impact: Briacell Therapeutics Corp. (NASDAQ:BCTX) priced its $30 million public offering at $5.59 per unit, leading to a 53% drop in its stock price to $5.09, reflecting market sensitivity to financing activities.
See More
Bank of America Reports Q4 Net Income of $7.6 Billion, Exceeding Expectations
- Earnings Highlight: Bank of America (BAC) reported a net income of $7.6 billion for Q4 FY2025, down from $6.8 billion a year ago, yet its EPS of 98 cents surpassed the analyst consensus estimate of 96 cents, indicating stable profitability amidst market fluctuations.
- Revenue Growth: The bank's revenue net of interest expense increased by 7% year-over-year to $28.532 billion, exceeding the analyst consensus estimate of $27.944 billion, reflecting strong performance and effective cost management in a competitive landscape.
- Market Dynamics: While U.S. stocks traded lower overall, with the Nasdaq Composite falling over 100 points, energy stocks rose by 0.9%, indicating a divergence in market performance that may present investors with opportunities to reassess their portfolios.
- Economic Indicators: U.S. retail sales increased by 0.6% month-over-month in November, marking the largest surge since July, suggesting a rebound in consumer spending that could positively impact future economic growth.
See More
Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%
- Glaukos Sales Projection: Glaukos Corp anticipates FY25 sales of $507 million, yet its shares fell 12.1% in pre-market trading, indicating market concerns about its growth outlook despite the positive sales forecast.
- Briacell's Sharp Decline: Briacell Therapeutics' announcement of a $30 million public offering led to a staggering 53.1% drop in its stock price during pre-market trading, reflecting investor apprehension regarding the financing strategy.
- Trip.com Investigation Impact: Trip.com Group confirmed it is under investigation by China's SAMR for potential anti-monopoly violations, resulting in a 9.3% decline in its pre-market stock price, which may adversely affect its market performance and investor confidence.
- Pearson Trading Update: Pearson PLC's trading update for 2025 caused its shares to drop 7.2% in pre-market trading, indicating a cautious market sentiment regarding its future performance.
See More
BriaCell Therapeutics Prices Public Offering at $5.59 per Unit for $30 Million
- Public Offering Details: BriaCell Therapeutics announced a public offering of 5.367 million units priced at $5.59 each, aiming for gross proceeds of approximately $30 million, which will fund working capital and general corporate purposes.
- Warrant Information: Each unit consists of one common share and one warrant, the latter allowing purchase of common shares at an exercise price of $6.93, expiring five years post-issuance, enhancing potential returns for investors.
- Stock Price Impact: Following the announcement, BCTX's stock plummeted 54.12% to $5.01, reflecting a highly negative market reaction despite a previous surge to $12.10 due to positive results in treating breast cancer patients.
- Future Trading Arrangements: The warrants have been approved for listing on the Nasdaq Capital Market, expected to begin trading under the symbol
See More
